Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study

Abstract

Since the approval of the COVID-19 vaccines, their safety and efficacy has been widely demonstrated in patients with cancer. However, there remain patients with reservations regarding vaccination. We aimed to assess genitourinary cancer patients’ perceptions of the vaccines as well as barriers and influencers of decision-making through the completion of a questionnaire. While vaccine-associated concerns were observed, most patients with genitourinary cancers were willing to receive the vaccine. Moving forward, differing strategies could be considered to enhance patient education on the utility of vaccination in the setting of cancer and beyond.

Keywords:

• COVID-19 vaccine
• genitourinary cancer
• vaccine hesitancy
• survey study

Declaration of Interest

Daniela V. Castro, Zeynep B. Zengin, Jasnoor Malhotra, Cristiane D. Bergerot, Luis Meza, JoAnn Hsu, Ameish Govindarajan, Neal Chawla, Alex Chehrazi-Raffle, Benjamin D. Mercier, Sean W. Chen, Matthew Feng, Sweta Prajapati, Kyle O. Lee, Errol J. Philip, and Sumanta K. Pal declare they have no conflicts of interest. Tanya B. Dorff, MD: Consulting/advisory—Exelixis, Janssen, Bayer, and BMS. Yung Lyou, MD, PhD: Consulting/advisory—Pfizer, EMD Serano, and Seattle Genetics. Nazli Dizman, MD: Consulting—Vivreon Biosciences.